Marginal Zone Lymphoma

What is marginal zone lymphoma?

Marginal zone lymphoma (MZL) is a group of slow-growing, or indolent, B-cell non-Hodgkin lymphomas. MZL can develop in different parts of the body, and symptoms and treatment can vary depending on the subtype and location. Many people have a slow course and may not need treatment immediately.

What type of MZL do I have, and why does the location matter?

There are three main types of marginal zone lymphoma. Extranodal MZL, also called MALT lymphoma, develops outside the lymph nodes and can occur in areas such as the stomach, salivary glands, lungs, skin, or around the eyes. Splenic MZL mainly involves the spleen and may also involve the blood or bone marrow. Nodal MZL primarily involves lymph nodes.

The subtype and location can affect both monitoring and treatment. For example, some stomach MALT lymphomas are associated with Helicobacter pylori (H. pylori), and treating that infection may also treat the lymphoma. Your oncology team will explain which subtype you have and why it matters for your care.

Why might I not need treatment right away?

Because MZL often grows slowly, some people who are not having significant symptoms may be monitored closely without starting treatment immediately. This is called active surveillance, watchful waiting, or observation. This does not mean your lymphoma is being ignored. Your care team will follow you with regular visits and testing and recommend treatment if the lymphoma begins causing problems or changes in a way that makes treatment appropriate.

How is MZL treated if I need treatment?

Treatment depends on the MZL subtype, where the lymphoma is located, how much disease is present, whether it is causing symptoms, previous treatments, and your overall health. Depending on the situation, treatment may include treating an associated infection, radiation therapy, antibody-based treatment, other medicines, or combinations of treatments.

Your oncology team will explain whether treatment is needed and which approach is most appropriate for you.

What should I expect during treatment?

Your experience will depend on the treatment you receive. Your care team may regularly check blood counts and other laboratory tests, monitor for side effects, and use imaging or other testing when appropriate to evaluate how the lymphoma is responding. Ask your oncology team which side effects are most likely with your particular treatment and which symptoms should prompt you to contact them.

Can MZL change over time?

MZL is usually slow-growing, but in some people it can transform into a faster-growing lymphoma, most commonly diffuse large B-cell lymphoma (DLBCL). Your oncology team watches for changes that might suggest the lymphoma is behaving differently.

Tell your care team about significant new changes such as a rapidly enlarging lymph node or mass, unexplained fever, drenching night sweats, unintentional weight loss, or other new or worsening symptoms.

What happens during long-term follow-up?

MZL often requires long-term monitoring. Depending on your situation, you may be followed during active surveillance, after treatment, or during a period of remission. Follow-up may include clinic visits, physical examinations, blood tests, and imaging or other testing when appropriate. Your oncology team will monitor for changes in the lymphoma, treatment effects, infections, and other health concerns over time.

Could a clinical trial be an option for me?

Clinical trials are research studies that evaluate new treatments or new ways of using existing treatments. Depending on the study, a clinical trial may be available at different points in your care. Participation is voluntary, and each trial has specific eligibility requirements.

Your oncology team can help you understand whether a clinical trial may be appropriate for your situation.

What if my MZL does not respond to treatment or comes back?

MZL can return after a period of remission or may sometimes not respond fully to a particular treatment. If this happens, there may be additional treatment options. The approach depends on your MZL subtype, previous treatments, how long the lymphoma was controlled, your overall health, and other features of your disease.

Your oncology team may discuss additional antibody-based or targeted treatments, other medicines, or clinical trials depending on your individual situation.